Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) slipped over -9% at $3.54. Arrowhead Pharmaceuticals, Inc. has 73.57 million shares outstanding, and in the last trade has seen ATR around 0.22. The volume of ARWR witnessed a shift from 5.15 million shares, based on a 50-day average, to 1.01 million shares. In the most updated research from a number of analysts on Wall Street, the company gets 2 Buys and 0 Sell among 4 analysts. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has consensus analyst target price is $3. That gives us a street projected return of -15.25%. If the published price targets set by Arrowhead Pharmaceuticals, Inc. analysts have any power to influence the stock’s share price, the highest price target set for ARWR is $6. Arrowhead Pharmaceuticals, Inc. most recently reported earnings per share (EPS) of -$0.07 for the June 2017 versus -$0.32 in the same quarter last year, representing -78% growth. Analysts had predicted -$0.14. Revenue during the quarter was $9.34 million, representing 23250% growth from $40000 in year-ago quarter. The company’s quarterly EPS surprised Wall Street by as much as -50% to the downside in its last earnings announcement, so investors should note this tendency when assessing consensus estimates. On a similar note, analysts expect EPS of -$0.13 in September 2017 quarter and -$0.14 in December 2017 quarter, representing -58.06% and -17.65% growth, respectively. They expect this year’s earnings to fall -66.41% year-over-year to -$0.44, followed by 84.09% growth in the next year to -$0.81. Shares of Workday, Inc. (NASDAQ:WDAY) traded down -7.16% in the last session while performance was up 106.54% in the last five days. The stock’s last price was lower from the average trading price of 50 days recorded at $107.95 while enlarging the period to 200 trading days, the average price was $98.34. Currently, 206.23 million total shares are owned by the public and among those 132.98 million shares have been available to trade. The percentage of shares being held by the company management was 1.3% while institutional stake was 0%. Workday, Inc. (WDAY) has risen 61.94% since then. But since then, those gains have faded by -8.85%. WDAY has lost -1.73% in the 1-month period. Arrowhead Pharmaceuticals, Inc. has a beta of 1.88, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$1.49 a share in the trailing twelve months. It last reported revenues of $525.32 million and EPS of $0.24 for the July 2017, representing 39% top-line growth and -0.04 EPS growth. Looking forward, the company’s quarterly earnings are expected to come at -$0.42 in the three months through October 2017 and -$0.42 in the quarter ending January 2018, reflecting -16% and -6.67% growth, respectively. For the full year, analysts expect earnings to decline -25.7% yoy to -$1.33. Next year this growth will reach 2.26% to attain -$1.36.
